There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen Inc (AMGN – Research Report) and Spero Therapeutics Inc (SPRO – Research Report) with bullish sentiments.
Amgen Inc (AMGN)
Cowen & Co. analyst Yaron Werber maintained a Buy rating on Amgen Inc yesterday and set a price target of $231. The company’s shares closed on Friday at $196.25.
According to TipRanks.com, Werber is a 4-star analyst with an average return of 10.7% and a 57.5% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Prevail Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amgen Inc with a $216.56 average price target, which is a 10.3% upside from current levels. In a report issued on July 31, Jefferies also maintained a Buy rating on the stock with a $230 price target.
Spero Therapeutics Inc (SPRO)
In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Spero Therapeutics Inc. The company’s shares closed on Friday at $9.23.
According to TipRanks.com, Baral is a 5-star analyst with an average return of 22.4% and a 47.8% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, Madrigal Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Spero Therapeutics Inc with a $27 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.